• Please log in or register to access this feature.

Original Article

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

  1. Darrell White MD1,†,*,
  2. Adetola Kassim MD2,
  3. Birbal Bhaskar MD3,
  4. Jing Yi PhD4,
  5. Karen Wamstad MSN4,
  6. Virginia E. Paton PharmD4

Article first published online: 18 JUL 2012

DOI: 10.1002/cncr.27745

Issue

Cancer

Cancer

Volume 119, Issue 2, pages 339–347, 15 January 2013

Additional Information

How to Cite

White, D., Kassim, A., Bhaskar, B., Yi, J., Wamstad, K. and Paton, V. E. (2013), Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer, 119: 339–347. doi: 10.1002/cncr.27745

Author Information

  1. 1

    Division of Hematology, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada

  2. 2

    Division of Hematology/Oncology, Vanderbilt Medical Center, Nashville, Tennessee

  3. 3

    Department of Oncology, Medical Oncology Care Associates, Orange, California

  4. 4

    Genentech, Inc., South San Francisco, California

  1. †

    Fax: (902) 473-4447

*Division of Hematology, Queen Elizabeth II Health Science Centre, Room 433, Bethune Building, 1276 South Park Street, Halifax, Nova Scotia, Canada B3J 2Y9

  1. †

    Fax: (902) 473-4447

Publication History

  1. Issue published online: 4 JAN 2013
  2. Article first published online: 18 JUL 2012
  3. Manuscript Accepted: 5 JUN 2012
  4. Manuscript Received: 30 APR 2012
  5. Manuscript Revised: 30 APR 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (230K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marco Rossi, Cirino Botta, Pierpaolo Correale, Pierfrancesco Tassone, Pierosandro Tagliaferri, Immunologic microenvironment and personalized treatment in multiple myeloma, Expert Opinion on Biological Therapy, 2013, 1

    CrossRef

View Full Article (HTML) Get PDF (230K)